EXELExelixis, Inc.

EXEL Stock Price, Valuation & Chart | Exelixis, Inc.

Compare

$62.230-0.60 (-0.95%)

At close · 16 Oct 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology

Overview Financials Dividends Ratios

EXEL Historical price chart

EXEL Key Stats

Market Capitalization15.64B

PE Ratio17.78

EPS3.5

Trading Volume2.64M

Today's High/Low63.39/61.75

Dividend Yield0.00

52 Week High/Low63.39/33.76

Shares Outstanding251.36M

EXEL Financial Statement

EXEL Analyst ratings

EXEL Analysis & performance metrics

EXEL Company profile

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United…

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients…

EXEL Management team

Name

Position

Christopher J. SennerCFO

Executive Vice President & Chief Financial Officer

Dana T. Aftab Ph.D.

Executive Vice President of Discovery and Translational Research & Chief Scientific Officer

Amy C. Peterson M.D.

Executive Vice President of Product Development & Medical Affairs and Chief Medical Officer

William Berg M.D.

Senior Vice President of Medical Affairs

Patrick Joseph Haley M.B.A.

Executive Vice President of Commercial

Anne Champsaur M.D.

Senior Vice President of Drug Safety

Susan T. Hubbard

Executive Vice President of Public Affairs & Investor Relations

Jeffrey J. Hessekiel J.D.

Executive Vice President & General Counsel

Name

Position

Christopher J. SennerCFO

Executive Vice President & Chief Financial Officer

Dana T. Aftab Ph.D.

Executive Vice President of Discovery and Translational Research & Chief Scientific Officer

Amy C. Peterson M.D.

Executive Vice President of Product Development & Medical Affairs and Chief Medical Officer

William Berg M.D.

Senior Vice President of Medical Affairs

Patrick Joseph Haley M.B.A.

Executive Vice President of Commercial

Anne Champsaur M.D.

Senior Vice President of Drug Safety

Susan T. Hubbard

Executive Vice President of Public Affairs & Investor Relations

Jeffrey J. Hessekiel J.D.

Executive Vice President & General Counsel

Management Team

Christopher J. SennerCFO

Executive Vice President & Chief Financial Officer

Dana T. Aftab Ph.D.

Executive Vice President of Discovery and Translational Research & Chief Scientific Officer

Amy C. Peterson M.D.

Executive Vice President of Product Development & Medical Affairs and Chief Medical Officer

William Berg M.D.

Senior Vice President of Medical Affairs

Patrick Joseph Haley M.B.A.

Executive Vice President of Commercial

Anne Champsaur M.D.

Senior Vice President of Drug Safety

Susan T. Hubbard

Executive Vice President of Public Affairs & Investor Relations

Jeffrey J. Hessekiel J.D.

Executive Vice President & General Counsel

Management

Christopher J. SennerCFO

Executive Vice President & Chief Financial Officer

Dana T. Aftab Ph.D.

Executive Vice President of Discovery and Translational Research & Chief Scientific Officer

Amy C. Peterson M.D.

Executive Vice President of Product Development & Medical Affairs and Chief Medical Officer

William Berg M.D.

Senior Vice President of Medical Affairs

Patrick Joseph Haley M.B.A.

Executive Vice President of Commercial

Anne Champsaur M.D.

Senior Vice President of Drug Safety

Susan T. Hubbard

Executive Vice President of Public Affairs & Investor Relations

Jeffrey J. Hessekiel J.D.

Executive Vice President & General Counsel

Total 8 executives

EXEL Frequently asked questions

What is Exelixis, Inc. (EXEL) Stock Price?

Current stock price of Exelixis, Inc. (EXEL) stock is $62.230. The stock price is -0.95% lower in the session. The intraday range can be seen from this page. Volume of Exelixis, Inc. (EXEL) stock is 2.64M.

Last updated at 16 Oct 2026, 08:00 pm.

Why is the Exelixis, Inc. (EXEL) stock price going up or down today?

The stock price of Exelixis, Inc. (EXEL) can change with earnings, company news, and overall market sentiment. Exelixis, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Exelixis, Inc. stock expensive at its current price?

Whether Exelixis, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for EXEL on this page is 17.78. EPS on this page is 3.50. Compare those figures with peers and growth expectations before deciding if the current Exelixis, Inc. price is justified.

How has the stock price of Exelixis, Inc. (EXEL) performed historically?

Historical performance for Exelixis, Inc. (EXEL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how EXEL reacted to past earnings and market events.

Should I buy Exelixis, Inc. (EXEL) stock, at this price?

Buying Exelixis, Inc. (EXEL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.